15-May-23

InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference

Mr. Rabinovitch is one of the global cannabis senior executives to participate NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure") today announced that Alexander Rabinovitch, CEO of InterCure,
15-May-23

InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA (1) of $6 Million Strong balance sheet with over $45 million cash and Net current assets of over $72 million NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE
15-May-23

InterCure to Be Featured with Mike Tyson in an Exclusive Interview on Fox Business

The Company will be featured on the Claman Countdown show on Monday to discuss its strong 2022 results and recent partnership with Mike Tyson NEW YORK and TORONTO and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: INCR ) (TSX: INCR.U) (TASE: INCR) ("InterCure'' or the "Company"), the
25-Apr-23

InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary

NEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company outside of North America announces that on April 24, 2023, it was informed
20-Apr-23

InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries

Leading Global Pharmaceutical Cannabis Company, InterCure, signed an initial collaboration agreement with legendary boxer, entrepreneur and cannabis advocate Mike Tyson’s premium cannabis brand NEW YORK and TORONTO and HERZLIYA, Israel, April 20, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd .
03-Apr-23

InterCure Reschedules 2022 Full Year Results Conference Call

NEW YORK , TORONTO , and HERZLIYA, Israel , April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the company's financial
31-Mar-23

InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

Record fiscal year 202 2 revenue of $ 150 million Record fiscal year 202 2 Adjusted EBITDA *  of $ 3 2 million Record fiscal year 202 2 net income of $ 17 million Generated $20 Million cash flow from operations Strong balance sheet with over $ 95 million cash NEW YORK, TORONTO, and HERZLIYA,
14-Feb-23

InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

NEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“ InterCure ” or the “ Company ”) the biggest and most profitable cannabis company outside of north America, announced today that it has filed a lawsuit
01-Feb-23

InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)

NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Company ") announces that, further to the merger agreement with Cann Pharmaceutical Ltd.